Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex
R Wienecke, I Fackler, U Linsenmaier, K Mayer… - American Journal of …, 2006 - Elsevier
R Wienecke, I Fackler, U Linsenmaier, K Mayer, T Licht, M Kretzler
American Journal of Kidney Diseases, 2006•ElsevierA 19-year old patient with tuberous sclerosis presented with a renal angiomyolipoma.
Because animal trials of tuberous sclerosis showed an effect of rapamycin on renal tumors,
our patient was administered rapamycin for 6 months. During this time, the renal
angiomyolipoma shrank significantly, regrew during an 8-month period, and decreased in
size again after readministration of rapamycin.
Because animal trials of tuberous sclerosis showed an effect of rapamycin on renal tumors,
our patient was administered rapamycin for 6 months. During this time, the renal
angiomyolipoma shrank significantly, regrew during an 8-month period, and decreased in
size again after readministration of rapamycin.
A 19-year old patient with tuberous sclerosis presented with a renal angiomyolipoma. Because animal trials of tuberous sclerosis showed an effect of rapamycin on renal tumors, our patient was administered rapamycin for 6 months. During this time, the renal angiomyolipoma shrank significantly, regrew during an 8-month period, and decreased in size again after readministration of rapamycin.
Elsevier